GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

If approved, the new presentation will offer a convenient administration option to healthcare professionals Globally, up to 1 in 3 adults will develop shingles in their lifetime 1,2,3,4 Over 25 ...

5 This European regulatory review follows the file acceptance by the US FDA on 8 January 2025 for the new prefilled syringe presentation, continuing GSK’s commitment to providing solutions to ...

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts.

GSK (GSK) and the University of Oxford announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer Immuno ...

when the partners teamed up to launch a new molecular and computational medicine institute. That collaboration formed on the back of a five-year, $40 million investment from GSK and focuses on ...

If approved by the EMA, this new option could streamline the vaccination process in clinical settings across Europe. GSK is a global biopharma company focused on uniting science, technology ...

Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

GSK)'s vaccine for shingles prevention. This new syringe presentation is designed to simplify the administration process for healthcare providers by eliminating the need to mix a powder and liquid ...

The company noted that the new presentation has the same composition as the reconstituted vaccine. The submission is based on data demonstrating comparability between the two. GSK's shingles ...

Learn More Pharmaceutical giant GSK is pushing the boundaries of what generative AI can achieve in healthcare areas like scientific literature review, genomic analysis and drug discovery.